Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs

Chemical Biology and Drug Design

Volumn 82, Issue 4, 2013, Pages 384-393

  Tian, Ye ^a   Rai, Diwakar ^a   Zhan, Peng ^a   Pannecouque, Christophe ^b   Balzarini, Jan ^b   De Clercq, Erik ^b   Liu, Huiqing ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1,2,6 thiadiazine 1,1 dione; Activity assay; HIV 1; Non nucleoside reverse transcriptase inhibitors; Reverse transcriptase; Synthesis

Indexed keywords

2,2 DIMETHYL 5 (2 (NAPHTHALEN 1 YL)ACETYL) 1, 3 DIOXANE 4,6 DIONE; 2,2 DIMETHYL 5 (2 PHENYLACETYL) 1,3 DIOXANE 4,6 DIONE; 2,6 2H 5 (NAPHTHALEN 1 YLMETHYL) 1,2, 6 THIADIAZINE 1,1,3 TRIONE; 2,6 2H 5 BENZYL 1,2,6 THIADIAZINE 1,1,3 TRIONE; 6 H 5 (NAPHTHALEN 1 YLMETHYL) 3 CHLORO 1,2,6 THIADIAZINE 1,1 DIONE; 6 H 5 BENZYL 3 CHLORO 1,2,6 THIADIAZINE 1,1 DIONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

1,2,6-THIADIAZINE-1,1-DIONE; ACTIVITY ASSAY; HIV-1; NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS; REVERSE-TRANSCRIPTASE; SYNTHESIS;

CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; THIADIAZINES;

EID: 84884818419     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12160     Document Type: Article

References (23)

1. Hirschel B., Francioli P. (1998) Progress and problems in the fight against AIDS. N Engl J Med;338:906-908.
2. Mugnaini C., Alongi M., Togninelli A., Gevariya H., Brizzi A., Manetti F., Bernardini C. et al. (2007) Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. J Med Chem;50:6580-6595.
3. Mai A., Artico M., Rotili D., Tarantino D., Clotet-Codina I., Armand-Ugoon M., Ragno R., Simeoni S., Sbardella G., Nawrozkij M.B., Samuele A., Maga G., Estee J.A. (2007) Synthesis and biological properties of novel 2-Aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains. J Med Chem;50:5412-5424.
4. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., Janssen P., De Corte B., Vingerhoets J., Pauwels R., de Bethune M.P. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother;48:4680-4686.
5. Guillemont J., Pasquier E., Palandjian P., Vernier D., Gaurrand S., Lewi P.J., Heeres J. et al. (2005) Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem;48:2072-2079.
6. Janssen P.A.J., Lewi P.J., Arnold E., Daeyaert F., de Jonge M., Heeres J., Koymans L. et al. (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2, 6dimethylphenyl] amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, rilpivirine). J Med Chem;48:1901-1909.
7. Miller C.D., Crain J., Tran B., Patel N. (2011) Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc);47:5-15.
8. Chen X., Zhan P., Dongyue L., Clercq E.D., Liu X. (2011) Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem;18:359-376.
9. Chen X., Zhan P., Liu X., Cheng Z., Meng C., Shao S., Pannecouque C., Clercq E.D., Liu X. (2012) Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem;20:3856-3864.
10. Yu M., Fan E., Wu J., Liu X. (2011) Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Med Chem;18:2376-2385.
11. Yu M., Liu X., Li Z., Liu S., Pannecouque C., Clercq E.D. (2009) Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2, 6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorg Med Chem;17:7749-7754.
12. Lansdon E.B., Brendza K.M., Hung M., Wang R., Mukund S., Jin D., Birkus G., Kutty N., Liu X. (2010) Crystal structures of HIV-1 reverse transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): implications for Drug Design. J Med Chem;53:4295-4299.
13. Li a., Liu X., Wang X., Liu J. (2011) Design, synthesis and anti-HIV-1 activity of 4, 6-dibenzyl-2-oxo-1, 2-dihydropyridine-3-carbonitrile. J Chin Pharm Sci;20:442-446.
14. Japan Pat., JP62042978A, 1978.
15. 3 Chlorination of 4-Quinazolones. J Org Chem;76:1653-1661.
16. Pannecouque C., Daelemans D., De Clercq E. (2008) Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc;3:427-434.
17. Popovic M., Sarngadharan M., Read E., Gallo R. (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science;224:497-500.
18. Clavel F., Guetard D., Brun-Vezinet F., Chamaret S., Rey M., Santos-Ferreira M., Laurent A., Dauguet C., Katlama C., Rouzioux C., Klatzmann D., Champalimaud J. L., Montagnier L et al. (1986) Isolation of a new human retrovirus from West African patients with AIDS. Science;233:343-346.
19. Roche Diagnostics GmbH, Roche Applied Science. (2010) Reverse Transcriptase Assay, Colorimetric. Mannheim, Germany: Roche Diagnostics GmbH, Roche Applied Science.
20. Das K., Bauman J.D., Clark A.D., Frenkel Y.V., Lewi P.J., Shatkin A.J., Hughes S.H., Arnold E. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci;105:1466-1471.
21. Das K., Clark A.D., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Vinkers H.M. et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem;47:2550-2560.
22. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev;46:3-26.
23. Ma X., Yang S., Gu S., He Q., Chen F., De Clercq E., Balzarini J., Pannecouque C. (2011) Synthesis and anti-HIV Activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors. ChemMedChem;6:2225-2232.